Hamid Reza Soltani*, Seyed Khalil Forouzannia, Mehdi Latif, Mehdi Hadadzadeh, Azadeh Shahidzadeh and Arezoo Shahidzadeh
Introduction: Clopidogrel improves intravascular stent patency reduces ischemic events but there are little data on its effect fallowing OPCAB. This study was designed to
Material and Method: In this randomized clinical trial, 413 patients undergoing OPCAB were randomized to receive aspirin 80 mg plus Clopidogrel 75 mg (n=214,
intervention group) or aspirin 80 mg (n=199, control group) for three days after surgery and then were treated in accordance with the common guidelines. Patients with
coagulation disorders and those who rejected taking drugs were excluded. The data were then analyzed by using Student t-test and Chi-square test through SPSS ver.
Result: Mean age of patients was 61.081 ± 10.84 years. There was no significant difference between in two groups in pre and perioperation data. Mean of bleeding in the
mean of bleeding during three days between two groups (p: 0.013).
Conclusion: According to our findings patients treated with Clopidogrel plus aspirin had significantly less bleeding compared with the group treated with aspirin alone
during three days. It seems that the effect of Clopidogrel on outcomes of operation is considerable and Clopidogrel can be introduced as a qualified supplement therapy
for aspirin although the side effect of recombinant antiplatelet therapy is also controversial.
Share this article
Journal of Surgery received 245 citations as per Google Scholar report